Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$3.20 USD
+0.07 (2.24%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.19 -0.01 (-0.31%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 83 | 81 | 113 | 17 | 22 |
Receivables | 17 | 10 | 9 | 6 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 18 | 14 | 9 | 4 | 4 |
Other Current Assets | 4 | 7 | 9 | 1 | 2 |
Total Current Assets | 122 | 112 | 141 | 29 | 41 |
Net Property & Equipment | 11 | 10 | 7 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1 | 2 | 3 | 1 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 36 | 38 | 39 | 41 | 42 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 180 | 176 | 191 | 78 | 89 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 12 | 11 | 9 | 5 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 13 | 17 | 13 | 7 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 6 | 4 | 4 | 4 |
Total Current Liabilities | 35 | 37 | 28 | 17 | 21 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 3 | 2 | 1 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 75 | 63 | 32 | 33 | 24 |
Non-Current Capital Leases | 1 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 6 | 8 | 7 | 8 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 69 | 64 |
Total Liabilities | 127 | 117 | 70 | 129 | 120 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 1 | 1 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 284 | 225 | 217 | 0 | 0 |
Retained Earnings | -230 | -167 | -96 | -52 | -31 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 54 | 59 | 121 | -51 | -30 |
Total Liabilities & Shareholder's Equity | 180 | 176 | 191 | 78 | 89 |
Total Common Equity | 54 | 59 | 121 | -52 | -31 |
Shares Outstanding | 49.00 | 37.90 | 37.20 | NA | NA |
Book Value Per Share | 1.10 | 1.55 | 3.26 | 0.00 | 0.00 |
Fiscal Year End for Akoya Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 45 | 62 | 83 | 79 |
Receivables | NA | 17 | 13 | 17 | 16 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 25 | 23 | 18 | 19 |
Other Current Assets | NA | 3 | 4 | 4 | 4 |
Total Current Assets | NA | 90 | 102 | 122 | 117 |
Net Property & Equipment | NA | 8 | 9 | 11 | 11 |
Investments & Advances | NA | 4 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 1 | 1 | 1 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 34 | 35 | 36 | 36 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 144 | 155 | 180 | 177 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 10 | 11 | 12 | 12 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 1 | 1 |
Accrued Expenses | NA | 13 | 12 | 13 | 13 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 7 | 7 | 7 |
Total Current Liabilities | NA | 33 | 33 | 35 | 36 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 3 | 3 | 3 | 3 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 76 | 75 | 75 | 64 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 4 | 6 | 5 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 122 | 122 | 127 | 115 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 289 | 286 | 284 | 281 |
Retained Earnings | NA | -267 | -254 | -230 | -219 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 22 | 33 | 54 | 62 |
Total Liabilities & Shareholder's Equity | NA | 144 | 155 | 180 | 177 |
Total Common Equity | 0 | 22 | 33 | 54 | 62 |
Shares Outstanding | 49.50 | 49.30 | 49.30 | 49.00 | 48.90 |
Book Value Per Share | 0.00 | 0.45 | 0.66 | 1.10 | 1.27 |